(PharmaNewsWire.Com, March 24, 2020 ) According to the new market research report "Glycomics / Glycobiology Market by Product (Enzymes (Glycosyltransferase, Glycosidase), Instruments (HPLS, Mass Spectrometry, MALDITOF), Kits & Reagents (Glycoproteins)), Application (Diagnostic, Drug Discovery, Oncology), End User - Global Forecast to 2021", published by MarketsandMarkets™, The global glycobiology market is expected to reach USD 1,211.4 million by 2021 from USD 649.5 million in 2016, at a CAGR of 13.3%.
Glycobiology products are widely used for analysis of cell surface markers, which can act as diagnostic or therapeutic targets. The base year considered for the study is 2015, and the forecast has been provided for the period between 2016 and 2021.
Key Players and Strategies Adopted by Them:
The key players in the glycobiology market include Agilent Technologies (U.S.), Bruker Corporation (U.S.), Danaher Corporation (U.S.), New England Biolabs (U.S.), ProZyme, Inc. (U.S.), Shimadzu Corporation (Japan), Merck KGaA (Germany), Takara Bio, Inc. (Japan), Thermo Fisher Scientific (U.S.), and Waters Corporation (U.S.).
Glycomics plays a crucial role in analyzing the molecular mechanism of various types of cancers. Glycomics also plays an important role in identifying new biomarkers for cancers. Biomarkers are used as key diagnostic targets for various types of cancers. They can also be used for devising novel and personalized therapies for cancer patients. Owing to its ability to differentiate between protein sub-types based on the molecular structure of their glycan patterns, glycomics has emerged as an important research tool for the discovery and validation of protein-based cancer biomarkers.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
